SCHEMBL10193138

SCHEMBL10193138

CNC1CCCC1c1ccc(Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.49
SLC6A4 P31645 8/20 0.49
SLC6A3 Q01959 8/20 0.49
CYP2D6 P10635 6/20 0.49
CYP2C9 P11712 2/20 0.49
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
CYP3A4 P08684 5/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 3/20 0.46
NPC1 O15118 2/20 0.46
MTOR P42345 2/20 0.46
RAB9A P51151 2/20 0.46
MLNR O43193 1/20 0.46
NR1I2 O75469 1/20 0.46
ABCB11 O95342 1/20 0.46
ESR1 P03372 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
ABCB1 P08183 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9843257 0.78 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6CYP2C9
SCHEMBL735409 0.75 SLC6A4 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4
SCHEMBL736813 0.75 GRIA4 (0.58) SLC6A2SLC6A4SLC6A3CYP2C9CYP3A4
SCHEMBL10192778 0.74 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL13983010 0.74 SLC6A3 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL16748038 0.74 KDM1A (0.42)
SCHEMBL10192763 0.73 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL11447010 0.73 TRPA1 (0.42) SLC6A2SLC6A4SLC6A3CYP2D6CYP2C9
SCHEMBL11447011 0.73 TRPA1 (0.42) SLC6A2SLC6A4SLC6A3CYP2D6CYP2C9
SCHEMBL13076110 0.73 GRIA4 (0.57) MEN1KMT2AADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138377-B2 Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use DOV PHARMACEUTICAL, INC. (US) 2012-03-20 US disclosed
US-20080293822-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use ETHISMOS RESEARCH, INC. 2008-11-27 US disclosed
US-20080269348-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use ETHISMOS RESEARCH, INC. 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293822-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use HTR2C, HTR1B, HTR3C SLC6A2 150/4885SLC6A4 93/4885SLC6A3 76/4885
US-20080269348-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use HTR2C, HTR1B, HTR3C SLC6A2 150/4885SLC6A4 93/4885SLC6A3 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.